|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1999-10-18
|
|
pubmed:abstractText |
L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct properties including a longer half-life and less immunogenic properties.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 1999 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1203-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10506705-Adult,
pubmed-meshheading:10506705-Aged,
pubmed-meshheading:10506705-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10506705-Asparaginase,
pubmed-meshheading:10506705-Drug Administration Schedule,
pubmed-meshheading:10506705-Enzymes, Immobilized,
pubmed-meshheading:10506705-Female,
pubmed-meshheading:10506705-Humans,
pubmed-meshheading:10506705-L-Lactate Dehydrogenase,
pubmed-meshheading:10506705-Male,
pubmed-meshheading:10506705-Methotrexate,
pubmed-meshheading:10506705-Middle Aged,
pubmed-meshheading:10506705-Philadelphia Chromosome,
pubmed-meshheading:10506705-Polyethylene Glycols,
pubmed-meshheading:10506705-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:10506705-Prednisone,
pubmed-meshheading:10506705-Recurrence,
pubmed-meshheading:10506705-Remission Induction,
pubmed-meshheading:10506705-Treatment Outcome,
pubmed-meshheading:10506705-Vincristine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
|
|
pubmed:affiliation |
The Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
